

THE HPV AND ANAL CANCER FOUNDATION LIMITED

TRUSTEES REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31st DECEMBER 2023

REGISTERED COMPANY NO: 07955451 (England and Wales)

REGISTERED CHARITY NO: 1147457

THE HPV AND ANAL CANCER FOUNDATION LIMITED

TRUSTEES REPORT

AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

CONTENTS

	<u>Page</u>
Reference and Administrative Details	1
Report of the Trustees	2-17
Independent Examiners' report	18
Statement of Financial Activities	19
Balance Sheet	20
Statement of Cash Flow	21
Notes to the Financial Statements	22-29

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023

Reference and Administrative Details For the Year ended 31 December 2023

LEGAL AND ADMINISTRATIVE INFORMATION

TRUSTEES	C Almada J Almada T Almada C Levett
REGISTERED OFFICE	128 City Road London EC1V 2NX
REGISTERED COMPANY NUMBER	07955451 (England and Wales)
REGISTERED CHARITY NUMBER	1147457
INDEPENDENT EXAMINER	Knox Cropper LLP 65 Leadenhall Street London EC3A 2AD
SOLICITORS	Stone King 16 St John's Lane London EC1M 4BS
BANKERS	HSBC 16 King Street Covent Garden London WC2E 8JF

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023

STRUCTURE, GOVERNANCE AND MANAGEMENT

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20th February 2012 and registered as a charity on the 25th May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The directors are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 28. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given an overview of the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws, and policies.

Risk Management

The trustees of the Foundation hold the responsibility of safeguarding the charity's assets and are satisfied that systems are in place to mitigate those risks which the charity may face.

FINANCIAL REVIEW

It is important to note that the parent and subsidiary organizations operate as one entity in achieving the mission of the organisation. The revenue for the charity is dependent on donations from the public. Income for the UK HPV and Anal Cancer Foundation in 2023 was £579,781 and expenditure was £342,973.

Total free reserves at the year end amounted to £281,655.

Reserves Policy

The Trustees have reviewed the amount of reserves it regards as a minimum prudent requirement. They have concluded that provision for three months operating reserves that enable the organisation to meet its financial commitments including grants, contracts and staff salaries is sufficient. This would allow time to manage cost reductions or generate funds as required whilst minimising the impact on service provision. At 31 December 2023 this amounted to £21,478. This indicates a healthy surplus of free reserves of £260,177, which will be allocated for use in 2024 and 2025 to support our initiatives to empower anal cancer patients, and accelerate prevention and research methods that eliminate human papillomavirus, and anal cancer.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

OBJECTIVES, ACTIVITIES AND ACHIEVEMENTS

Public Benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities.

History

The Foundation was first established in the USA in 2010 by three siblings who lost their mother, aged 53, to stage IV HPV-related anal cancer. Frustrated by the limited therapeutic and community support available to her, they created the organisation to fill the void caused by scant public, scientific and medical focus on this disease and its cause, the human papillomavirus (HPV). HPV causes anal cancer and at least five other cancers, amounting to 5% of cancers worldwide. These cancers are preventable. In 2012, the organization expanded to the UK with 2013 as its first full operational year.

Mission

The HPV and Anal Cancer Foundation empowers anal cancer patients and accelerates prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Objectives

- Highlight the relevance of human papillomavirus (HPV) in contracting cancer;
- Advocate for prevention methods that will end anal cancer and HPV-related cancers, including gender-neutral vaccination;
- Accelerate a cure for the 5% of all cancers that are caused by HPV, with a focus on anal cancer; and
- Provide support for survivors, caregivers, scientists and providers connected to anal cancer.

The Need

A fundamental objective of the Foundation's work is to reduce the incidence of anal cancer and other HPV-related cancers. HPV is a very common skin virus that nearly every sexually active person will get at some point in their lives. HPV affects both men and women and is responsible for 5% of the world's cancer burden. HPV causes cancers of the anus, cervix, head and neck, penis, vagina, and vulva.

Protection against HPV through universal HPV vaccination is a critical public health goal. With HPV identified as a cause of six different types of cancer, and 5% of cancer cases worldwide, it is imperative that we protect the entire population against it. The most effective method to reduce cancers related to HPV is to prevent initial infection of the virus through immunisation. The Foundation achieves this important aim through its efforts to advance equal access to HPV protection for both boys and girls through gender-neutral vaccination against the virus. At the introduction of the vaccine in most countries, only girls were able to receive this life-saving intervention while boys were generally excluded. The Foundation created and led the coalitions in the US and UK to ensure all children have equal access to protection against these cancers. The US achieved the milestone of recommending HPV protection to all children in 2011. Following the Foundation's five-year advocacy campaign in the UK, school-based HPV vaccination for boys began in September 2019. Our focus is on securing the same protection for boys as well as girls across Europe, and beyond.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

While we work to prevent future cases, it is also fundamental that scientific and medical disparities are addressed for the population that will continue to be diagnosed with HPV-related cancers like anal cancer. Treatment options have barely progressed since the 1970s and minimal research has been undertaken in new therapies. The medical and scientific communities need better research tools and investment in novel ideas to develop a cure.

The stigma surrounding anal cancer remains one of the central challenges to improving outcomes for anal cancer patients. Unfortunately, many medical centres provide only limited information specific to the experience of anal cancer. Many patients feel isolated and lack the support and educational resources that significantly improve quality of life during and after treatment.

Strategies to Achieve Our Goals

We achieve our mission in the UK and US through collaboration with scientists, clinicians, survivors, organisations, and government agencies; education of stakeholders and the general public; survivor support; and investment in the medical and scientific community to end HPV and the cancers it causes. Specifically, we take action to destigmatize and raise awareness about HPV, HPV-related cancers, and anal cancer; increase access to the HPV vaccine; improve screening protocols and preventative care; empower anal cancer thrivers; and accelerate a cure for anal cancer and other HPV-related illnesses.

Key achievements in 2023

NOMAN is an Island: Race to End HPV

The NOMAN Campaign raises awareness about the HPV-related cancer epidemic in men and women and educates about the importance of universal HPV vaccination, while challenging participants to extreme endurance races across the world. It is through such extreme feats of athleticism that NOMAN honour the struggle and isolation that many cancer patients feel.

NOMAN has been an incredibly successful campaign. Since its inaugural event in 2013 with the Barcelona – Ibiza: Row to End HPV, over 200 individuals – and their hundreds of supporters – have embraced the cause and our values. These NOMAN have raised awareness about HPV cancers on a local, national and international scale, as well as funds to support our programmes.

2023 was a special year for the foundation as the 10th anniversary of the NOMAN campaign. Book-ending our event calendar, NOMAN riders took on the Haute Route events at Crans-Montana and Ventoux. The Haute Route is the world's most prestigious cycling event for amateur cyclists. The races provided unparalleled experiences with 3-,5-and 7- day professional road cycling events in the most iconic cycling destinations worldwide. During the 3-day events, riders take on some 300km and 8000m+ of vertical ascent, testing themselves against the most infamous climbs in the world, all in the name of raising awareness of HPV-related cancers. Additionally, at each event all participants, (nearly 3000 participants in total) are given our END HPV socks to light up the climbs and generate conversation about our work to eliminate HPV cancers. NOMAN co-founder Tristan Almada also spoke about our mission to eliminate HPV cancers at the pre-stage briefing.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

July saw the 10th anniversary edition of the Barcelona-Ibiza: Row to End HPV, our flagship event. NOMAN's ocean rowing race pits teams of amateur rowers against each other in a three-day sprint across the Mediterranean. Rowing across an ocean is like no other sport: it is as much about the crews' ability to cope mentally as it is about technique and physical strength. The race has seen great interest among adventure seekers, and rowers range from people with no prior experience to more seasoned rowers looking to attempt an ocean row before committing to a longer challenge such as the Pacific or Atlantic Oceans.

2023 saw great interest from our community, and the return of participants from previous editions looking to be part of this special anniversary race, alongside new supporters of our work. They were joined on the water by Olympic gold medallist, Will Satch MBE as our NOMAN ambassador whose participation generated increased interest and support for our cause.

We are grateful for the generosity of the Trafigura Foundation for their tremendous support of our campaign and the Foundation's work in 2023 in the form of a matching contribution of \$150,000.

We look forward to building on these initiatives in the coming years.

HPV Action Europe Network

In 2018 and 2019 the Foundation was involved in discussions to establish an advocacy campaign in Europe to introduce gender-neutral vaccination across the region and completely eliminate HPV-related diseases.

NOMAN has partnered with the European Cancer Organisation (ECO) to achieve this mission. ECO works to reduce the burden of cancer and improve outcomes and the quality of care for patients through multidisciplinary initiatives. As the European not-for-profit federation of member organisations working in cancer, they convene oncology professional and patients to agree on policy, advocate for positive change, and be the united voice of the European cancer community.

Together with ECO, the Foundation looks forward to working with European policy makers to end the suffering caused by HPV cancers. In 2021, we achieved a major milestone by securing for the first time, a commitment to eliminate HPV cancers in Europe's Beating Cancer Plan. The HPV Action Network has built on this major success with the following achievements in 2023, including supporting advocacy work in countries that are falling behind.

Publication of the 2nd edition of the HPV Policy Prevention Atlas

On 22 June, 2023, the HPV Prevention Policy Atlas was launched at the Romanian Parliament. This latest update of the Atlas, initially published in 2020, led by the European Parliamentary Forum for Sexual and Reproductive Rights (EPF) scores 48 European governments on their approach to HPV prevention – primary prevention (vaccination), secondary prevention (screening), and online information. The tool aims at providing up-to-date publicly available information across all countries of WHO European region in line with WHO cervical cancer elimination strategy and Europe's Beating Cancer Plan. The 2nd edition highlights the geographical disparities which exist in HPV prevention policies across the WHO European region, as highlighted by the visible East-West divide in EPF's scores across the continent.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

The Atlas serves as a powerful call to action; underlining the need for action to tackle HPV, in particular via policies related to HPV immunisation, cervical screening and online information, and underlines the importance of implementing the goals of Europe's Beating Cancer Plan.

Out of 48 countries in geographical Europe:

39 countries (83%) offer a national routine vaccination programme.

30 countries (64%) provide gender-neutral vaccination.

23 countries (49%) maintain an HPV vaccination registry.

25 countries (53%) offer easy-to-find, government-hosted websites with good or excellent information on HPV prevention.

In 2023, Denmark, Sweden, Finland, the UK, and Ireland are the top-performing countries in HPV prevention. These nations have implemented best-practice policies, including national routine HPV vaccination programs that are gender-neutral and freely available, resulting in high vaccination rates supported by robust immunisation data systems. They also offer free HPV screening for adults and maintain public websites with clear, factual information provided by authorities. Conversely, countries like Kosovo and Azerbaijan are at the bottom of the list, marked by a lack of primary and secondary prevention policies and an absence of reliable, evidence-based information on HPV prevention.

The Atlas has been presented at several high-level events throughout the year including the Serbian Parliament, and in a presentation to senior politicians and policymakers in Poland in October 2023.

The Atlas is available: <https://www.epfweb.org/node/552>

Launch of HPV Action Croatia and Romania and support for HPV Coalition, Bulgaria

In 2023, the HPV Action Network began supporting advocacy campaigns on HPV elimination in Romania, Croatia and Bulgaria to see more young people vaccinated against HPV, in line with the recommendations of Europe's Beating Cancer Plan, and cervical screening programmes established in each country.

Eastern European countries fall behind many other European countries in their efforts to eliminate HPV cancers, with low levels of HPV immunisation and cervical screening. Each month, the HPV Action network organises video conferences bringing together physicians, scientists, public health experts, and representatives of mothers and young people from all over the respective countries in order to address and identify opportunities for improvement. In country coordinators have been appointed in 2023 to support the coalitions and identify areas of need and opportunity. At the ECO Summit in November 2023, work in Romania, Bulgaria and Croatia was discussed at a well-attended satellite meeting, including by the Deputy Health Minister of Bulgaria.

Specific achievements for each of the countries in 2023 are detailed below.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

Romania

HPV Action Romania – (Acțiunea HPV România) is helping national organisations and institutions to mobilise and join forces to implement policies aimed at increasing HPV vaccination, screening and information coverage. A wide range of organisations have come together as part of this new campaign, whose call to action is focused on three points:

- Routine gender-neutral HPV vaccination for all 11-18-year-olds with 90% uptake by 2030.
- A national population-wide cervical cancer screening programme, based on HPV testing and including self-sampling as an option for hard-to-reach groups and others, with 70% of women screened by the age of 35 and again by age 45, to be achieved by 2030.
- A sustained public education campaign promoting HPV awareness, vaccination and screening.

In 2023:

- In the context of World Cancer Day (4th February) a debate was held with parliamentarians focusing on the theme of "Women's Cancers – Directions for Improving Prevention, Early Diagnosis, and Early Access to Treatment to Reduce Incidence and Improve Survival Rates", in order to identify public health opportunities to decrease cancer incidence and improve survival rates. HPV immunisation and screening are key tools in the public health toolkit to address these issues.
- In May, a public awareness campaign was launched in Romanian football stadiums, reaching thousands of fans with our critical message about the dangers of HPV and its link to at least six different types of cancer. The objective of this campaign is to heighten awareness and encourage vaccination, in particular through encouraging parents to protect their children by asking their doctors about the immunisation.
- HPV Action Romania was officially launched, and an in-country coordinator appointed, on 31 October at the HPV Action Now event in the Romanian Parliament in Bucharest. At the event, Romania's health minister, Alexandru Rafila, announced that by the end of 2023, HPV immunisation would be fully reimbursable by the state for all boys and girls 11 to 18 years old. Although there are still barriers such as delivery and distribution, as well as combating public misunderstanding and misinformation, this commitment is a significant step forward.

Croatia

Croatia introduced GNV in 2016, but immunisation coverage is well below WHO elimination targets of 90%. In 2023:

- Croatian policymakers were invited to an event in early October with the coalition of national supporters of HPV prevention, highlighting the means by which national and local organisations can support advocacy efforts to encourage uptake of vaccination in order to prevent HPV cancers. On 20 October, the group participated in the '**Stakeholder Forum "Better Health for All: EU Global Health Strategy"**', overviewing the upcoming plans for the Coalition and presenting the aims of the upcoming cervical cancer screening programs in Croatia.
- Throughout 2023, the coalition was represented in interviews on 'Good Morning Croatia', which have emphasised the preventability of HPV cancers through immunisation, and have highlighted the underutilisation of HPV vaccines among young people, to a national audience.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

HPV Action Croatia was officially launched on 6 December at the Croatian parliament hosted by Ivan Čelić, MP, and virtually via YouTube. Bringing together experts from epidemiologists, researchers, patients, civil society groups the aim is to create a united approach to improve preventive policies in HPV.

Bulgaria

In Bulgaria, the HPV Action Now project aims at bringing together, uniting and supporting organisations and institutions that work towards HPV vaccination and cervical cancer screening.

This campaign will be coordinated with the Bulgarian HPV Coalition, a national expert non-governmental coalition actively supported by the World Health Organization. It's objectives are:

- Raising public awareness around the risk of contracting the virus;
- Encouraging regular screening;
- Achieving a high level of vaccination, in accordance with WHO recommendations.

In 2023:

- On 19 September, representatives of the HPV Action Network and Bulgarian HPV Coalition had a fruitful meeting in Sofia at the Bulgarian Parliament where local MPs were encouraged to continue efforts towards HPV prevention through vaccination.
- Held on 10-12th November, HPV Action Network representatives spoke at the second Bulgarian national conference on vaccine-preventable diseases, the largest event ever held in the country dedicated to these topics. Organised by the Bulgarian HPV Coalition and Astra Forum Foundation, leading specialist in vaccination and prevention convened to discuss progress and challenges within Bulgaria.

Protect Europe

The EU4Health programme was adopted as a response to the COVID-19 pandemic and to reinforce crisis preparedness in the EU. The pandemic highlighted the fragility of national health systems. The EU4Health programme will bring a contribution to the long-term health challenges by building stronger, more resilient and more accessible health systems, through financial support from the European Union.

Through this funding, the PROTECT-EUROPE project will champion gender-neutral HPV vaccination in the EU to protect everyone against HPV cancers, by providing information and guidance to EU Member States on:

- How healthcare professionals can better communicate directly with young people and their parents or caregivers.
- How public health messaging on HPV can be tailored to better resonate with young people and their parents or caregivers.
- How other innovative approaches, such as bundling various adolescent vaccines, could improve HPV vaccine uptake.

A key element of the project is ensuring that boys as well girls are offered the vaccine. Gender-neutral HPV vaccination is one of the flagship commitments of Europe's Beating Cancer Plan. Findings from this project will contribute to the HPV Action network as they become available.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

Response to European Commission call for evidence on action to promote vaccination against cancer causing viruses.

The HPV Action network supported a response to the European Commission Call for Evidence on cancer prevention – action to promote vaccination against cancer-causing viruses. The consultation invited public feedback on future initiatives to increase the uptake of vaccination against the Hepatitis B virus and Human Papillomavirus.

The call for evidence will support the drafting of the European Commission proposal for a Council Recommendation on vaccine-preventable cancers, which will be published by the end of 2023. The HPV Action Network emphasised the following points for inclusion in the upcoming Recommendation:

1. Accelerating the achievement of HPV cancer elimination through gender-neutral vaccination.
2. Increasing coverage of HBV vaccination including for new-borns, children and risk-groups.
3. Ensuring an inequalities focus throughout the recommendation.
4. Actively tracking and monitoring progress towards the achievement of HPV and HBV cancers elimination goals.
5. Enhancing EU level action against misinformation and disinformation about vaccination on social media.
6. Supporting a stable supply environment for HPV and HBV vaccines across Europe.
7. Creating synergies between the European Commission and the World Health Organization in implementing policies and strategies for the elimination of all cancers and diseases caused by HPV and HBV.
8. Urging Member States to adopt public health strategies that include multi-stakeholders educational campaigns.
9. Committing Member States to further facilitate access to vaccination and to implement coordinated vaccination catch-up programmes among the population.
10. Securing long-term commitment by the European Union to the funding of vaccine-preventable cancers research.

Future plans

In 2024 and beyond, the HPV Action Network will:

- Complete the PROTECT-EUROPE project and utilise the outputs wherever possible for Action Now.
- Continue to support the national campaigns in Bulgaria, Croatia and Romania and actively consider expanding the approach into Poland and other countries where possible.
- Hold an Advocacy Symposium on 25 January and publish a follow-up report. We will learn the lessons from the symposium for our own advocacy work and encourage others to utilise the outputs for their own campaigns on HPV policy.
- Respond to the forthcoming EC proposal for an EU Council Recommendation on vaccine-preventable cancers.
- Continue to disseminate and use as an advocacy tool the EPF/ECO HPV Prevention Policy Atlas.
- Use ECO's Time to Accelerate Manifesto and the Men and Cancer Roadmap to raise HPV issues during the European Parliament elections.
- Continue to participate in the Mission Board on vaccination chaired by Prof Walter Ricciardi.
- Participate in International HPV Awareness Day and European Immunisation Week.
- Explore other opportunities to maximise our impact.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

HPV Coalition UK

In October 2022, the NOMAN Campaign were proud to join forces with Jo's Cervical Cancer Trust to launch and co-chair the HPV Coalition in the United Kingdom. The Coalition was officially launched in the Palace of Westminster in an event hosted by long standing HPV advocate, Jess Phillips MP, and supported by politicians from both sides of the aisle, as well as community stakeholders such as HPV cancer survivors.

The HPV Coalition is an expert advisory group of leading patient groups, professional groups, clinicians, and expert individuals who have come together to inform and advance the UK's journey towards elimination of HPV-related cancers – cancers which account for 5% of all cancers globally, and which we now, for the first time in history, have the opportunity to eliminate as a public health threat.

Despite the scale of the opportunity, the UK has yet to take the step of other countries, such as Australia and Canada, in developing an action plan for cervical cancer elimination. The UK also lags behind the European Union which, through the Beating Cancer Plan, has gone one step further, in committing to eliminate all HPV cancers. The HPV Coalition is therefore eager to see the UK put in place a concrete plan for elimination as a matter of priority, targeted at the whole range of HPV-related cancers and supporting access to preventative interventions for all parts of the population.

The Coalition will stand at the forefront of UK policymaking and will bring together a membership of patient organisations, professional groups, clinicians, and expert individuals to build and demonstrate broad stakeholder consensus around the significant – and as yet unharnessed – opportunity to pursue elimination in the UK. The membership will advocate for commitment and action from all UK governments to pursue elimination of the whole range of HPV-related cancers, in both men and women.

Publication of the 'Roadmap towards making the elimination of all HPV-related cancers a reality across the UK'

In May 2023, the Coalition published a Roadmap towards making the elimination of all HPV-related cancers a reality across the UK. This sets out ambitious, yet realistic goals, mapping out key areas of action, including milestones, markers of success, and research recommendations for areas which require further understanding.

The Roadmap serves as a call to Governments across the four nations of the UK to take action, while providing the blueprint of how elimination can be delivered. The goal is simple: Make the elimination of all HPV-related cancers a reality across the UK. We have many of the tools available to us now to make this a reality, and we must ensure it is grasped without delay.

To achieve this, we must ensure foundations of HPV prevention are strengthened. The Roadmap is therefore made up of a number of building blocks – with associated actions – that plot a course to elimination:

1. National and regional leadership and accountability
2. Improving education on HPV to tackle stigma and drive access to prevention
3. Making sure everyone has equitable access to screening and early diagnosis
4. Restoring and boosting immunisation uptake, including catch-up programmes
5. Enhancing the data, digital and workforce infrastructure
6. Embracing future innovations

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

It is critical that UK governments set out a concrete strategy for the elimination of all HPV-related cancers, widening the scope of our ambition beyond cervical cancer elimination. Along with our fellow members of the HPV Coalition, we stand ready to support the implementation of recommendations and take meaningful steps to prevent HPV-related cancers from affecting the lives of so many women and men.

Upon its publication, the Roadmap received national media coverage at launch, including an OpEd authored by the Foundation's CEO David Winterflood in The Times. It has also enabled the Coalition to engage with policy and parliamentary stakeholders to facilitate wider consensus around the roadmap and the ultimate goal of elimination. This included securing a Westminster Hall debate on HPV vaccination attended by MPs, and meetings with UK Health Security Agency (UKHSA) the government agency responsible for England-wide public health protection and infectious disease capability, NHS England, and an invitation to 10 Downing Street to brief the Prime Minister's Health Adviser.

In November 2023, NHS chief executive Amanda Pritchard pledged to eliminate cervical cancer by 2040, a key step in the journey to the elimination of all HPV cancers. In December, NHS England's first ever Vaccination Strategy was published containing a positive focus on improving HPV vaccination coverage rates.

In 2024, the Coalition will engage with NHS England as a partner in the implementation of the elimination ambition, to ensure that HPV prevention stays at the top of the agenda should there be a change of government. We will work with local systems to improve HPV prevention, and to advocate for similar commitments towards elimination in the devolved nations.

You can read the roadmap here: <https://www.nomancampaign.org/post/hpv-coalition-roadmap-to-elimination>

Leading the charge for global gender-neutral HPV vaccination

In 2023, a record number of countries added boys into their HPV vaccination programmes, alongside girls. But gender-neutral HPV immunisation programmes, the most effective means we have to prevent HPV cancers, are still only utilised in the minority of programmes globally. If this year is anything to go by, it won't be the case for long.

In the past year we have seen increased vaccine supplies made available, new studies highlighting the effectiveness of gender-neutral immunisation, increased calls for inclusion on vaccine equity and gender-equality grounds, and the opportunity to speed up progress towards the elimination of cervical cancer, and in turn all HPV cancers. Yet there is still work to be done. NOMAN continues to lead global advocacy efforts for the inclusion of boys into countries' HPV immunisation programmes. In 2023, we joined the Global HPV Consortium's launch in Kuala Lumpur to scope out the framework to take global action on HPV cancers, spoke at a panel discussion in Belgium: Elimination of HPV Cancers: Dream or Reality? (REALITY!), in addition to partnering with Global Action on Men's Health (GAMH), as discussed below.

Making the case for global gender-neutral HPV vaccination

In 2023 we announced a new partnership between NOMAN is an Island: Race to End HPV Campaign and Global Action on Men's Health (GAMH), an organisation dedicated to promoting health and well-being on a global scale. Together, we are embarking on a mission to ensure global universal access to gender-neutral HPV vaccination, a vital step towards a healthier future for all.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

Why is this partnership crucial? HPV-related diseases affect millions worldwide, irrespective of gender. HPV can cause a range of cancers - cervical, anal, penile, vaginal, vulvar, head and neck - as well as genital warts and recurrent respiratory papillomatosis (RRP). Yet gender-neutral HPV vaccination, despite now being a 'flagship' cancer prevention policy in the European Union (as detailed in Europe's Beating Cancer Plan, 2021), is still only the gold standard of protection in a minority of HPV vaccination programmes. In most countries with an HPV vaccination programme, only girls are vaccinated. Gender-neutral vaccination remains a controversial policy, especially for lower-income countries with very high rates of cervical cancer, and is not yet fully recommended by the World Health Organisation or supported by GAVI.

By focusing only on the vaccination of girls to prevent cervical cancer, girls-only programmes fail to protect males sufficiently from the cancers caused by HPV. They also fail to protect unvaccinated women from infection by men, a particular problem in countries with low vaccination rates in girls. Girls-only programmes also mean that they unfairly shoulder the responsibility for prevention. With vaccine supply increasing, single-dose programmes changing cost-effectiveness calculations and new evidence showing that 21% of males have a high-risk (cancer-causing) HPV infection (Buni L. et al, 2023), we believe it is time to make the case for gender-neutral vaccination on a global basis.

By advocating gender-neutral HPV vaccination, we are not only safeguarding the health of current generations, male and female, but also paving the way for a future where HPV-related cancers and diseases are relics of the past.

Working in collaboration, GAMH and NOMAN's partnership in 2023/2024 will entail:

- Developing an evidence-based case for gender-neutral HPV vaccination globally.
- Identifying the key stakeholders for partnership and advocacy in each WHO region with a focus on those regions with fewest countries offering gender-neutral vaccinations.
- Building an international alliance for action on gender-neutral HPV vaccination.

Anal Cancer Foundation

Anal cancer is one of the fastest growing cancers in the United States, and steadily increasing in the United Kingdom. We continue to work tirelessly to make life better for families facing anal cancer through our programs to raise awareness, accelerate early detection, improve quality of life, and advance a cure. This year, we made incredible progress raising awareness about the need to reform how anal cancer thrivers are diagnosed and treated.

Peer to Peer Support Programme and Thriver Education

In the UK, about 1,500 people, and in the US, about 10,500 are diagnosed with anal cancer annually. Anal cancer incidence is increasing and affects more people across the world every year. The social stigma that anal cancer carries prevents fair and equitable conversation, awareness, and funding to support research and care for people with the disease.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

Support and information is limited for anal cancer thrivers (our word for survivors) and many thrivers never meet another anal cancer patient. The Foundation provides educational forums and a peer mentoring program to support thrivers to close this gap. The Peer to Peer Support Program is a free service provided by the Foundation in the UK and USA to connect patients and caregivers facing the challenges brought on by anal cancer with a peer who has undertaken the same journey.

Connections are available for anyone at any cancer stage from newly diagnosed to years after treatment. Volunteers listen and help thrivers through their cancer journey by sharing their own experiences on treatment, stigma and social experiences relating to an anal cancer diagnosis. The programme's goals are to improve the lives of those affected by anal cancer and give survivors a voice and a community. The program also matches caregivers together. At the end of 2023, the HPVACF's Peer to Peer Support Program included 1199 thrivers, caregivers, and peer mentors. Our online educational events continue to provide hope and resources for thrivers. Our 'Taking Care of You: Managing Side Effects From Treatment For Anal Cancer' event, featuring expert clinicians who treat people living with anal cancer as well as a panel of thrivers has been viewed by over 5,900 people by the end of 2023. 'Living and Thriving After Treatment for Anal Cancer: Addressing Long Term Side Effects', was viewed 11,000 times by the end of the year.

Anal Cancer Patient Conference

On October 21st, 2023, the Anal Cancer Foundation held the second Anal Cancer Patient Summit.

Medical professionals spoke about anal cancer causes, treatments, and how to mitigate the various side effects of chemoradiation. We also heard from advocates who taught us, through sharing their own stories, how to use our personal experiences to advance the fight against anal cancer. Finally, thrivers were able to network both in groups and within one-on-one sessions which, for many people, was the first time they were meeting a fellow thriver.

The conference was created to provide an annual opportunity for anal cancer patients and caregivers to learn from medical professionals, connect with experts and each other, and take action to empower themselves and this community.

Over 449 people registered for the conference from 22 countries around the world.

Anal Cancer Foundation Co-Founder Justine Almada facilitated the day's events. Experts including Kevin Du, Cathy Eng, and Paul Romesser spoke about anal cancer causes, treatments, emerging therapies, and quality of life after treatment. Thrivers were given the opportunity to ask questions live, as well as to connect with one another.

We would like to make sure every family facing anal cancer has access to the same information as their doctors. Recordings of the day's events are now available on YouTube and has 1500 views since their publication.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

International Anal Neoplasia Society (IANS)

IANS, the International Anal Neoplasia Medical Society, creates medical guidelines and supports research essential to preventing and treating anal cancer. IANS was created with a seed grant from the Foundation.

IANS mission is to provide a forum for individuals with a broad spectrum of background, viewpoints and geographic origin, an exchange of ideas and dissemination of knowledge regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.

In support of this mission IANS:

- Develops position papers regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Represents the consensus opinion of IANS regarding the above topics to other professional societies, public organizations, regulatory authorities and governmental bodies.
- Encourages the development of a robust research agenda on the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Develops educational materials and conduct training courses that encourage the entry of a broad spectrum of clinicians into the field of anal neoplasia, and that furthers the development and depth of skills of clinicians needed to optimally diagnose, treat and prevent anal neoplasia.
- Develop educational materials for patients with anal neoplasia.

Information and Connection

The Foundation's anal cancer program website features a wealth of resources and is a source of information, support, and inspiration for patients and families affected by anal cancer.

Our focus is ensuring patients get the information and support they need during their anal cancer journey. Our *Living with Anal Cancer* section features information for patients at all stages of the anal cancer journey from newly diagnosed to post-treatment resources, such as how physical therapy can help with anal cancer treatment recovery. The site is the most comprehensive source of information on side effects and side effect mitigation during and after anal cancer treatment. This digital hub is populated with personal thriver stories (patients' stories of their experiences), information about helpful medical resources, and professional medical bodies, as well as connections to other patients and caregivers through our Peer to Peer Support Program.

Our goal in 2023 continued to be ensuring that more anal cancer thrivers have access to the information they need to face their cancer journey through targeted outreach based on our existing supporter base and a newsletter series for patients and caregivers, focused on our expert and popular resources. Our communications strategy continues to focus on consistency and providing "useful" information, with content covering treatment and research updates, stories from community members, and explainers of our services and how we support the anal cancer community.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

ACF's 2023 direct impact includes:

- 185 new anal cancer thrivers and caregivers signing up to be matched through the Peer-to-Peer Support Program.
- 330 anal cancer thrivers and caregivers helped by the 1:1 Patient Navigation Service. Peer to Peer Support signups in 2023 are up 49% on 2020 figures.
- 7 thrivers sharing their story publicly with our community through our Share Your Story Initiative.
- 650+ people participating in our informational forums.

Overall, in 2023, ACF directly served over 1,100 anal cancer patients through our best-in-class patient programs, at no cost to them.

Going forward, we will continue working to provide all the support the anal cancer community needs.

Looking Ahead: 2024

As we look ahead, the HPV and Anal Cancer Foundation continues to seek the most effective methods to prevent HPV and cure the cancers it causes.

The Foundation will continue to work tirelessly to eliminate all HPV-related cancers by furthering public policy and scientific debate, eliciting further professional and expert support, encouraging the development of regional initiatives on vaccinating boys, and demonstrating why it is important to protect all children against HPV at the recommended age.

The UK began vaccinating boys against HPV in September 2019 and we will continue to work with stakeholders in the HPV-related disease space to ensure that uptake for this cancer-preventing intervention among 12–13-year-old boys is as high as possible, rebounding from the disruption to immunisation programmes caused by the pandemic, by using the collective knowledge of the HPV Coalition's membership to ensure that the opportunity to eliminate HPV cancers in the UK

Our advocacy efforts in Europe with the European Cancer Organisation and HPV Action Network to attain gender neutral HPV vaccination across the continent, continue apace. With the EU Beating Cancer Plan specifically including actions on HPV cancers within its remit, we have a mandate to gain support and empower stakeholders within member states to eliminate HPV cancers. With over 40% of cancers in the region preventable, the extension of HPV vaccination programmes to protect boys as well as girls provides a recognised and effective means to tackle cancer. By continuing to build our evidence base, seeking and identifying barriers to uptake in EC member countries, harnessing the possibilities presented by Europe's Beating Cancer Plan and launching advocacy groups in member states, we are confident that more countries will sign up to gender neutral protection initiatives. Additionally, we will build on these national and regional endeavours, by taking our campaign global in 2024, working with Global Action on Men's Health will develop an evidence-based case for global gender-neutral HPV vaccination, and utilising high-level symposiums such as World Health Assembly week and the World Cancer Congress to build recognition, and an international alliance for gender-neutral HPV vaccination.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

Through the NOMAN is an Island Campaign, collaborations with advocates and legislators, media attention and athletic event participation, a broader audience is understanding the importance of protecting all children against HPV. With the NOMAN side of the organisation leading on HPV-related activities, our platform is growing from which to broadcast our message.

We will continue to push for legislative, research and policy changes to end anal cancer and improve the lives of those affected by it. We are excited by the response to our Patient Summit and "Ask the Expert" sessions and look forward to providing more touchpoints for our community in 2024. Our Peer-to-Peer support program retains its importance in supporting and empowering anal cancer survivors and caregivers. Utilizing digital and live platforms, we will reach a wider proportion of the anal cancer community, enabling patients to gain answers to the concerns they have and to connect to other anal cancer patient experiences.

We thank all of our donors and look forward to continuing the mission to empower anal cancer patients and accelerate prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees (who are also the directors of The HPV and Anal Cancer Foundation Limited) for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently
- observe the methods and principles in the Charity SORP
- make judgements and estimates that are reasonable and prudent
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant information of which the charitable company's examiners are unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the examiners are aware of that information.

The independent examiner, Knox Cropper LLP, will be proposed for re-appointment at the forthcoming Annual General Meeting.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

APPROVAL

This report was approved by the Board of Directors and Trustees on 26 September 2024 and signed on their behalf by:


.....
T Almada - Trustee

INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF THE HPV AND ANAL CANCER FOUNDATION LIMITED

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2023.

Responsibilities and basis of report

As the trustees of the charitable company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act'). You are satisfied that the accounts of the Company are not required by charity or company law to be audited and have chosen instead to have an independent examination.

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Company's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the Company's gross income exceeds £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a registered member of ICAEW which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Richard Billinghamurst
Knox Cropper LLP
Chartered Accountants
65-68 Leadenhall Street, London, EC3A 2AD

Date: 26/09/2024

THE HPV AND ANAL CANCER FOUNDATION LIMITED

STATEMENT OF FINANCIAL ACTIVITIES
(INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	Unrestricted Funds	Restricted Funds	2023 Total Funds	2022 Total Funds
		£	£	£	£
INCOME AND ENDOWMENTS FROM					
Donations and Legacies	2	122,220	-	122,220	90,094
Other Trading Activities	3	457,311	-	457,311	64,776
Investment Income		250	-	250	22
Total		<u>579,781</u>	<u>-</u>	<u>579,781</u>	<u>154,892</u>
EXPENDITURE ON					
Raising Funds	4	95,515	-	95,515	16,407
CHARITABLE ACTIVITIES	5				
Care and Support		47,757	-	47,757	47,957
Awareness Raising & Education		192,337	-	192,337	103,849
Research for a Cure		7,364	-	7,364	4,796
TOTAL		<u>342,973</u>	<u>-</u>	<u>342,973</u>	<u>173,009</u>
NET INCOME/(EXPENDITURE)		236,808	-	236,808	(18,117)
RECONCILIATION OF FUNDS					
Total Funds Brought Forward		44,847	13,100	57,947	76,064
TOTAL FUNDS CARRIED FORWARD		<u>£281,655</u>	<u>£13,100</u>	<u>£294,755</u>	<u>£57,947</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED
(REGISTERED COMPANY NUMBER: 07955451)

BALANCE SHEET

AS AT 31st DECEMBER 2023

	Notes	2023 £	2022 £
FIXED ASSETS	12	-	-
CURRENT ASSETS	13		
Debtors		1,791	831
Cash at Bank and in hand		301,944	67,779
		<u>303,735</u>	<u>68,610</u>
CREDITORS: Amounts falling due within one year	14	(8,980)	(10,663)
NET CURRENT ASSETS		<u>294,755</u>	<u>57,947</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			57,947
NET ASSETS		<u>£294,755</u>	<u>£57,947</u>
FUNDS	16		
Unrestricted Funds		281,655	44,847
Restricted Funds		13,100	13,100
TOTAL FUNDS		<u>£294,755</u>	<u>£57,947</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 26 September 2024 and were signed on its behalf by:



 T Almada – Trustee

THE HPV AND ANAL CANCER FOUNDATION LIMITED

STATEMENT OF CASH FLOW
FOR THE YEAR ENDED 31 DECEMBER 2023

	2023	2022
	£	£
OPERATING ACTIVITIES		
Net income/(expenditure) for the reporting period	236,808	(18,117)
Depreciation charge	-	-
Interest payable	-	-
Investment income	(250)	(22)
(Increase)/decrease in debtors	(960)	(504)
Increase/(decrease) in creditors	(1,683)	2,594
Net cash provided by/(used in) operating activities	<u>233,915</u>	<u>16,049</u>
INVESTING ACTIVITIES		
Investment income	250	22
Purchase of equipment	-	-
Net cash provided by/(used in) investing activities	<u>250</u>	<u>22</u>
FINANCING ACTIVITIES		
Repayment of borrowing	-	-
Cash inflows from new borrowing	-	-
Cash flows from financing activities	<u>-</u>	<u>-</u>
Change in cash and cash equivalents in the reporting period	234,165	(16,027)
Cash and cash equivalents at the beginning of the reporting period	67,779	83,806
Cash and cash equivalents at the end of the reporting period	<u>301,944</u>	<u>67,779</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31st DECEMBER 2023

1. ACCOUNTING POLICIES

Basis of Preparation of Accounts

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

Financial Reporting Standard 102 – reduced disclosure exemptions

The Charitable company has taken advantage of the following disclosure exemptions in preparing these Financial statements, as permitted by FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

- The requirements of Section 7 Statement of Cash Flows.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible Fixed Assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Ocean rowing boat and accessories – over 3 years.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund Accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purpose within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2023

1. ACCOUNTING POLICIES - continued

Fund Accounting

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension Costs and Other Post-Retirement Benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Judgements and Key Sources of Estimation Uncertainty.

No judgement (apart from those involving estimates) have been made in the process of applying the above accounting policies that have significant effect on amounts recognised in the financial statements.

2. GRANTS AND DONATIONS

	2023	2022
	£	£
Grants	10,000	85,158
Donations and gift aid	112,220	4,936
	<u>122,220</u>	<u>90,094</u>

3. OTHER TRADING ACTIVITIES

	2023	2022
	£	£
Fundraising Events	<u>457,311</u>	<u>64,776</u>

4. RAISING FUNDS

Raising Donations and Legacies

	2023	2022
	£	£
Staff Costs	6,990	6,585
Development Expenses	32	42
Donor Software Subscription	3,246	2,167
Event Expenses	83,139	4,626
Support Costs	2,108	2,987
	<u>95,515</u>	<u>16,407</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2023

5. CHARITABLE ACTIVITIES COSTS

	Direct Costs	Grant Funding of Activities (see note 6)	Support Costs (see note 7)	2023 Totals
	£	£	£	£
Care and Support	40,826	-	6,931	47,757
Awareness Raising & Education	158,820	22,934	10,583	192,337
Research for a Cure	3,828	-	3,536	7,364
	<u>203,474</u>	<u>22,934</u>	<u>21,050</u>	<u>247,458</u>

	Direct Costs	Grant Funding of Activities (see note 6)	Support Costs (see note 7)	2022 Totals
	£	£	£	£
Care and Support	31,802	-	16,155	47,957
Awareness Raising & Education	65,467	17,069	21,313	103,849
Research for a Cure	3,092	-	1,704	4,796
	<u>100,361</u>	<u>17,069</u>	<u>39,172</u>	<u>156,602</u>

6. GRANTS PAYABLE

	2023	2022
	£	£
Awareness Raising & Education	<u>£22,934</u>	<u>£17,069</u>

The total grants paid to institutions during the year was as follows

	2023	2022
	£	£
European Cancer Organisation	17,934	17,069
Global Action on Men's Health	5,000	-
	<u>22,934</u>	<u>17,069</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2023

7. SUPPORT COSTS

	2023	2022
	£	£
Bank charges	301	410
Pensions	-	4,984
Rent and rates	7,212	5,724
Insurance	306	276
Fees and subscriptions	828	606
Office costs	741	333
Sundries	400	-
Travel and meetings	7,658	968
Staff training	-	52
Consultancy fees	-	20,600
Conference expenses	-	2,146
Independent examination fee	4,980	5,100
Accountancy and legal fees	732	960
	<u>£23,158</u>	<u>£42,159</u>

8. NET INCOME (EXPENDITURE)

	2023	2022
	£	£
Net Income/(Expenditure) is stated after charging/(Crediting):		
Independent Examiner's Fee	<u>£4,980</u>	<u>£5,100</u>

9. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2023 nor for the year ended 31 December 2022.

Trustees' Expenses

There were no trustees' expenses paid for the year ended 31 December 2023 nor for the year ended 31 December 2022.

10. STAFF COSTS

	2023	2022
	£	£
Wages and Salaries	40,295	42,567
Social Security Costs	4,955	4,956
Other Pension Costs	1,350	1,356
	<u>£46,600</u>	<u>£48,879</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2023

10. STAFF COSTS – continued

The average monthly number of employees during the year was as follows:

	2023	2022
Average monthly employees	1	1

No employees received emoluments in excess of £60,000.

The key management personnel of the charity are those persons having authority and responsibility for planning, directing and controlling the activities of the charity, directly or indirectly, including any trustee of the charity and, in the case of the charity, includes the Director of UK Operations. Total employee benefits paid to key management personnel in the period amounted to £45,250 (2022: £47,523).

11. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted Funds £	Restricted Funds £	Total Funds £
INCOME AND ENDOWMENTS FROM			
Donations and Legacies	90,094	-	90,094
Other Trading Activities	64,776	-	64,776
Investment Income	22	-	22
Total	<u>154,892</u>	<u>-</u>	<u>154,892</u>
 EXPENDITURE ON			
Raising Funds	16,407	-	16,407
 Charitable Activities			
Care and Support	47,957	-	47,957
Awareness Raising & Education	103,849	-	103,849
Research for a Cure	4,796	-	4,796
Total	<u>173,009</u>	<u>-</u>	<u>173,009</u>
 NET INCOME/(EXPENDITURE)	 (18,117)	 -	 (18,117)
 RECONCILIATION OF FUNDS			
Total Funds Brought Forward	62,964	13,100	76,064
 TOTAL FUNDS CARRIED FORWARD	<u>£44,847</u>	<u>£13,100</u>	<u>£57,947</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2023

12. TANGIBLE FIXED ASSETS

	Plant and Machinery £
COST	
At 1 January 2023 and 31 December 2023	<u>47,250</u>
DEPRECIATION	
At 1 January 2023 and 31 December 2023	<u>47,250</u>
NET BOOK VALUE	
At 31 December 2023	<u>-</u>
At 31 December 2022	<u>-</u>

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023 £	2022 £
Gift Aid Recoverable	<u>1,791</u>	<u>831</u>

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023 £	2022 £
Deferred Income	4,000	5,922
Accrued Expenses	4,980	4,741
	<u>£8,980</u>	<u>£10,663</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2023

15. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted Funds	Restricted Funds	2023	2022
	£	£	£	£
Current Assets	272,675	13,100	303,735	68,610
Current Liabilities	(8,980)	-	(8,980)	(10,663)
	<u>£281,655</u>	<u>£13,100</u>	<u>£294,755</u>	<u>£57,947</u>

COMPARATIVE

	Unrestricted Funds	Restricted Funds	2022	2021
	£	£	£	£
Current Assets	55,510	13,100	68,610	84,133
Current Liabilities	(10,663)	-	(10,663)	(8,069)
	<u>£44,847</u>	<u>£13,100</u>	<u>£57,947</u>	<u>£76,064</u>

16. MOVEMENT IN FUNDS

	Brought forward	Income	Expenditure	At 31.12.23
	£	£	£	£
Unrestricted Funds				
General Fund	44,847	579,781	(342,973)	281,655
Restricted Funds				
Research for a Cure	13,100	-	-	13,100
TOTAL FUNDS	<u>£57,947</u>	<u>£579,781</u>	<u>£(342,973)</u>	<u>£294,755</u>

Net Movement in Funds, included in the above are as follows:

COMPARATIVE	Brought forward	Income	Expenditure	At 31.12.22
	£	£	£	£
Unrestricted Funds				
General Fund	62,964	154,892	(173,009)	44,847
Restricted Funds				
Research for a Cure	13,100	-	-	13,100
TOTAL FUNDS	<u>76,064</u>	<u>£154,892</u>	<u>£(173,009)</u>	<u>£57,947</u>

Capital Fund

The HPV and Anal Cancer Foundation Limited has shareholder capital equal to £1 and is owned by HPV and Anal Cancer Foundation, a registered charity in the United States of America, EIN 27-3217520.

Research for a Cure Fund

The Fund was set up to award grants to research which will advance development of effective treatments for anal and all HPV-related cancers.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2023

17. RELATED PARTY DISCLOSURES

No remuneration was paid to the trustees in the year (2022: £NIL).

A number of trustees gave donations to the Charity during the year. There were no conditions attached to those donations. The aggregate donations given to the Charity by related parties was £35,400.

18. GOING CONCERN

The Trustees have considered the effect of the current economic climate on the Charity's activities. The Charity currently holds a comfortable level of reserves, and its fixed costs are not significant. It has the ability to align its activities to the level of reserves available. The Trustees are optimistic about the fundraising outlook for the next twelve months.